KYMERA THERAPEUTICS INC

Kymera Therapeutics, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. CEO Nello Mainolfi will discuss the company's progress and 2025 milestones. A live webcast will be available on Kymera's website, with a replay archived post-event. Kymera focuses on targeted protein degradation to develop new therapies for immunological diseases.

Kymera Therapeutics advances its immunology pipeline with KT-621 (STAT6) Phase 1 trial initiation, expecting data by mid-2025. Sanofi expands KT-474 (IRAK4) Phase 2 trials for HS and AD, aiming for completion by mid-2026. KT-295 (TYK2) selected for Phase 1 trials in 2025. Company shifts focus to immunology, with $911M cash extending runway to mid-2027.

Kymera Therapeutics reported $10.3M revenue, $745M cash balance, and a financial runway into 2027. Progressing KT-474 into Phase 2 trials, it faces competition and clinical trial risks. Encouraging data presented at medical meetings, with a focus on developing effective, safe oral treatments.